BioVentrix, Inc. (BVXX)
BioVentrix will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
BioVentrix is a medical device company focused on developing, manufacturing and commercializing proprietary devices to restore left ventricular function in heart failure patients with reduced ejection fraction.
Our lead device program, the Revivent System, has a CE mark in Europe and is in its pivotal trial in the United States.
BioVentrix, Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 5 |
| CEO | David Richmond & Steven Chartier |
Contact Details
Address: 120 Forbes Blvd., Suite 125 Mansfield, MA 02048 United States | |
| Phone | (925) 290-1000 |
| Website | bioventrix.com |
Stock Details
| Ticker Symbol | BVXX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | usd |
| CIK Code | 0001283259 |
| Employer ID | 20-0372415 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David Richmond | Chairman, Co-Chief Executive Officer, and Chief Financial Officer |
| Steven Chartier | President, Co-Chief Executive Officer, and Director |
| Dr. Ori Ben-Yehuda | Chief Medical Officer |
| Mark Ravich | Independent Director |
| Dr. Rishi Puri | Independent Director |
| Dr. William Abraham | Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 12, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Nov 4, 2025 | D/A | Filing |
| Oct 6, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 5, 2025 | DRS | [Cover] Draft Registration Statement |
| Jul 8, 2025 | D/A | Filing |
| Oct 15, 2024 | D | Notice of Exempt Offering of Securities |
| Aug 29, 2024 | D/A | Filing |
| Mar 29, 2024 | D | Notice of Exempt Offering of Securities |
| Apr 4, 2023 | D | Notice of Exempt Offering of Securities |